Power3 initiates validation study of NuroPro diagnostic test

The clinical validation study will be a blinded study of Power3’s NuroPro diagnostic test, which is a blood test for the detection of Alzheimer’s and Parkinson’s disease. The study includes one hundred Alzheimer’s disease patients, one hundred Parkinson’s disease patients and one hundred controls. The Parkinson’s disease patients in the clinical validation study will augment the Parkinson’s disease validation study presently ongoing with the Research Institute of Thessaly in Greece.

The NuroPro is based on Power3’s discovery of a group of fifty-nine proteins in the blood that demonstrate significant differences in blood serum concentration for patients with Alzheimer’s and Parkinson’s disease. In blood serum, these protein biomarker combinations, when measured by blood serum proteomics, will lead to a more effective diagnosis and treatment of Alzheimer’s and Parkinson’s disease. Power3 expects expect to launch the NuroPro test for Alzheimer’s disease and Parkinson’s disease at the conclusion of this clinical validation study, which is expected to be late in calendar year 2008.

Steve Rash, CEO of Power3, said: “We are on the brink of offering these blood serum-based tests that will meet a tremendous need for early detection methods for breast cancer and neurodegenerative diseases.”